Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema

Emel Aygören‐Pürsün; Anette Bygum; Vesna Grivcheva‐Panovska; Markus Magerl; Jochen Graff; Urs C. Steiner; O. Fain; Aarnoud Huissoon; Tamar Kinaciyan; Henriette Farkas; Ramón Lleonart; Hilary Longhurst; William Rae; Massimo Triggiani; Werner Aberer; Mauro Cancian; Andrea Zanichelli; William Smith; M. L. Baeza; A. Du‐Thanh; Mark Gompels; Teresa Gonzalez‐Quevedo; Jens Greve; Mar Guilarte; Constance H. Katelaris; Sylvia Dobo; Melanie Cornpropst; D. Clemons; Fang Lei; Phil Collis; William Sheridan; Marcus Maurer; Marco Cicardi

doi:10.1056/nejmoa1716995

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Once-daily oral administration of BCX7353 at a dose of 125 mg or more resulted in a significantly lower rate of attacks of hereditary angioedema than placebo. Mild gastrointestinal symptoms were the principal side effect. (Funded by BioCryst Pharmaceuticals; APeX-1 ClinicalTrials.gov number, NCT02870972 .).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Aygören‐Pürsün et al. (2018) studied this question.

synapsesocial.com/papers/69de7a917ed287395e55902d https://doi.org/10.1056/nejmoa1716995

View Full Paper

Ask AI

Bookmark

Share

Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema

Ask about this paper

Abstract

Discussion

Cite This Study

Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading